Wednesday, September 3, 2014
The Sabin Vaccine Institute (Sabin) today announced that its product development partnership (Sabin PDP) successfully completed a Phase 1 clinical trial in Brazil of Na-GST-1/Alhydrogel®, a vaccine candidate for human hookworm, one of the most pervasive neglected tropical diseases (NTDs) affecting the world’s poor. The Sabin PDP is based at Sabin Vaccine Institute and Texas Children’s Hospital Center for Vaccine Development at Baylor College of Medicine in Houston, Texas. …read the whole press release here
Monday, September 1, 2014
As some of the world’s most urgent health threats, diseases such as polio, Ebola and influenza have of late received much publicity. Nevertheless, recent studies reveal that anaemia is also emerging as a worrying health disparity, especially among women and children living in poverty. Although perhaps not as dramatic as the infections mentioned above, anaemia has been shown to have devastating and long-term effects on childhood cognition and intellect, and to increase the risk of maternal morbidity and mortality.
Remko van Leeuwen, Martin Grobusch and Peter Hotez briefly explain why the HOOKVAC programme is now needed more than ever in the article [pdf] Tackling hookworm head-on published in ‘[pdf] Progress through Partnership: The UvA and Africa‘.
For people living in the poorest countries in Asia, Oceana, Latin America and Africa, hookworm, one of the neglected tropical diseases (NTD), is one of the leading causes of anemia. Today more than 400 million people suffer from hookworm, making it one of the most common conditions among people living in poverty. [read more at source]
New published information reveals that intestinal worm infections rank among the most common afflictions of people living in extreme poverty. The numbers are quite astonishing. More than 800 million people are currently believed to harbor Ascaris roundworms in their gastrointestinal tract, while around 450 million people are infected with either hookworms or Trichuris whipworms.
Read more on this story from the Huffingtonpost.
A new study published in Nature Genetics, led by a team of researchers at the Washington University School of Medicine in St. Louis, reveals that the hookworm’s genome has been decoded. These new developments will greatly aid scientists dr. Peter Hotez and dr. Bin Zhan at the Sabine Vaccine Institute, who focus on how different hookworm genes are responsible for invading humans, feeding on human blood and bypassing the host’s immune system. These findings have the potential to lead to new advancements and are welcome given how human hookworm, a neglected tropical disease (NTD), plagues nearly 700 million of the world’s poorest people. [Read More at the Sabine Vaccine Institute Blog]
Approximately 600-700 million people are infected by hookworm, primarily in sub-Saharan Africa, Southeast Asia, and Latin America. Hookworm infection ranks number one in terms of Years Lost from Disability from a neglected infectious disease, and among the top 3 in terms of lost Disability-Adjusted Life Years.
HOOKVAC will be developing the first and only vaccine for human hookworm infection. A bivalent, low-cost vaccine candidate will be clinically tested for the first time in an African disease endemic population. This will be done in Gabon in a very typical setting within the Central African rainforest belt, where the incidence of hookworm infections is 30%. Inspired by preparatory research, HOOKVAC believes that it can develop the vaccine with at least 80% efficacy against moderate and heavy hookworm infections that lasts at five years after immunization. Cost effectiveness modelling has shown that such a vaccine will significantly improve the efficacy of the current mass drug administration programs. HOOKVAC will play a crucial role in advancing toward large scale efficacy studies in African endemic areas.
Read more about the Human Hookworm Vaccine Project.